BridgeBio Oncology’s Pedro Beltran plans 1,870-share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported that Pedro Beltran, identified as a director and officer, filed notice of a proposed sale of 1,870 shares of common stock for an aggregate market value of $3,627.80. The approximate sale date is November 18, 2026. The shares were acquired from the issuer as restricted stock units on October 1, 2026. The notice lists August 19, 2026 as the plan-adoption or instruction date under Rule 10b5-1.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the reported Rule 10b5-1 date for Pedro Beltran’s BBOT sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.